Adagio Medical Q2 2025 net loss $3.9M; FULCRUM-VT enrollment at 85%

Adagio Medical Holdings, Inc.

2025-Q2 EPS reported -$0.86

Net loss narrowed to $3.9M ($0.26 basic EPS) from $5.7M in Q2 2024; revenue figure not disclosed.
Cash and equivalents of $8.2M as of June 30; cash burn reduced via corporate prioritization.
FULCRUM-VT pivotal study enrollment surpassed 85% of 206 patients; completion expected H2 2025.
First-in-human PARALELL PFCA results published in Journal of Cardiovascular Electrophysiology.
R&D expense down 31% to $2.0M; SG&A down 29% to $2.4M year-over-year.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.